Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade

HIGHLIGHTS

• What: As assessment using images has shown promising results as a prognostic biomarker in stage IV the authors aim to study the applicability of parameters also in treatment. In this analysis the authors focus on the impact of especially the presence of_(LSMM) on patients` and occurrence of events (AEs). In the current work, the authors assessed low skeletal muscle mass (LSMM) CT-based with the SMI threshold proposed by Prado et_al: and amp;lt; 52.4 ­cm2/m2 for male patients and and amp;lt; 38.5 c­ m2/ m2 for female patients (Prado et_al 2008 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.